DNA Q3 2021 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$412M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+483.4% YoY

Gross Profit

$55M71.3% margin

Operating Income

-$27M-34.4% margin

Net Income

-$102M-131.3% margin

EPS (Diluted)

$-3.08

QoQ Revenue Growth

+77.9%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$11M

Stock-Based Comp.

$127,000

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$533M

Stockholders' Equity

$1.6B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$13M	+483.4%
Gross Profit	$55M	$12M	+379.6%
Operating Income	-$27M	-$34M	+22.5%
Net Income	-$102M	-$26M	-291.0%

Revenue Segments

Service

$34M80%

Product

$8M20%